Mechanistically, we found that the combination therapy increased the number of Prf1- and GzmB-expressing CD8+ T cells, increased tumoral GzmB expression, and decreased tumor cell proliferation (Figure 3, B–D, and Figure 4, B–D). The gene discussed is PRF1; the disease is neoplasm.